INOVAIT announces third round of funding for artificial intelligence and image-guided therapy projects

Jun 21, 2023
Inside the computer room for an MRI system, peering out the window into an MRI room.

June 21, 2023 | Toronto, ON – INOVAIT, the pan-Canadian network for image-guided therapy (IGT) hosted by Sunnybrook Research Institute (SRI) and funded by the Government of Canada’s Strategic Innovation Fund, is pleased to announce 14 awarded projects that are part of the third round of its Pilot Fund.

The Pilot Fund projects focus on integrating artificial intelligence (AI) and machine learning (ML) into IGT technologies to tackle various diseases and illnesses, using different imaging modality techniques and therapies. Through these advancements, the network aims to bolster Canada’s medtech sector as a global leader and to improve the health outcomes of Canadians. The awardees of the Pilot Fund are eligible to receive up to $125,000 for their projects.

“We are thrilled to continue growing the most innovative IGT projects in Canada to promote commercial translation of research,” says Dr. Kullervo Hynynen, INOVAIT co-executive director and vice president of research and innovation at SRI. “Through this round of INOVAIT Pilot Fund projects, we are allocating over $1.6 million towards these 14 new projects to advance Canada’s image-guided therapy sector.”

A total of $6.3 million combined investment from public and private sources will support these 14 new projects. To date, INOVAIT has provided funding for 61 projects across the IGT sector in Canada. These projects involve collaborations between small- and medium-sized enterprises, hospital research centres, and academic institutions throughout Canada.

Pilot Fund projects were selected by INOVAIT’s expert review committee based on their scientific merit, potential for commercialization, economic impact, and benefit to healthcare. Awardees included NZ Technologies in Vancouver, British Columbia, and Tenomix in London, Ontario.

  • NZ Technologies, in collaboration with Kinetix Medicine, is working on a project to increase the efficiency and accuracy of ultrasound image-guided interventions by improving interaction with medical equipment and accuracy of needle visualization. They will achieve this by designing a novel display device to implement AI-driven touch-free screen technology and AI and ML algorithms for ultrasound image enhancement and real-time needle tracking.
  • Tenomix, in collaboration with Western University, is building a technology platform using robotics, ultrasound imaging, & AI/ML to automate the manual lymph node search process for surgically removed colon cancer tissues. Their automated device will make searching for lymph nodes less labour intensive, less costly, and more reliable for pathology labs, leading to better informed treatment decisions for cancer patients.

“Our government knows that the advances made possible by AI research will enable innovation in all areas of scientific advancement as well as in all aspects of our daily lives” says the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry. “That’s why we’re thrilled to partner with INOVAIT to help fund innovative new projects that will apply the power of AI and machine learning to concrete health innovations, improving the efficiency and accuracy of diagnoses and treatments, and leading to better patient outcomes for Canadians. Congratulations to the teams of the 14 Pilot Fund awarded projects!”

In the coming months, INOVAIT will announce a new call for applications for funding. More details about this funding opportunity will be provided. We encourage you to subscribe to the INOVAIT mailing list to be the first to hear about these opportunities. Visit our website to learn more about INOVAIT.

For any INOVAIT inquiries, please contact us at [email protected] .

Click to view a list of the projects selected for the Pilot Fund.

About INOVAIT

Established in 2020, INOVAIT invests strategically in collaborative partnerships that build upon Canada’s strength in digital innovation and health science research to create a critical mass of world-leading Image-Guided Therapy (IGT) companies. Led by the Sunnybrook Research Institute and supported by the Government of Canada’s Strategic Innovation Fund, the network brings together small, medium-sized, and large companies, research organizations, post-secondary institutions, and not-for-profit organizations. Its objective is to build a truly integrated IGT ecosystem by fuelling continuous innovation that revolutionizes healthcare globally.

 

About Sunnybrook Research Institute

Sunnybrook Research Institute (SRI) is the research arm of Sunnybrook Health Sciences Centre, an internationally recognized academic health sciences centre fully affiliated with the University of Toronto. With well-established programs in basic and applied sciences which span across three scientific platforms and ten clinical programs, SRI is developing innovations in care for the more than 1.3 million patients the hospital cares for annually. Recognized as a Centre of Excellence in focused ultrasound, SRI has one of the most comprehensive and successful focused ultrasound research programs in the world, with technical, scientific, and clinical experts accelerating progress in the field.

Share this on social media

Learn more about the network

PulseMedica is laser-focused on tackling vitreoretinal diseases

PulseMedica is laser-focused on tackling vitreoretinal diseases

The PulseMedica platform is a 3D image-guided therapy device that integrates powerful laser therapy, advanced medical imaging, and limitless machine learning (ML) for precision imaging and treatment of vitreoretinal disease. Vitreoretinal diseases exist within the clear gel (vitreous fluid) that fills the eye and retina at the back of the eye. PulseMedica’s device strives to automate the imaging and treatment process, enabling quick and precise disease targeting, thereby reducing the treatment time and reducing the risk of side effects and total time per patient, allowing for more patients to be treated each day.

Sonic Incytes is making liver screening more accessible 

Sonic Incytes is making liver screening more accessible 

Sonic Incytes, a Canadian artificial intelligence (AI)-assisted medical imaging company based out of Vancouver, British Columbia, is looking to change the way liver disease is screened and monitored globally. Their flagship, FDA cleared device, Velacur™, is revolutionizing the diagnosis and management of chronic liver disease. Their proprietary technology that grew into Velacur was originally developed by researchers at the University of British Columbia (UBC).